Compare AbCellera Biologics Inc (ABCL) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $10.05 (market cap $2.99B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.37. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VWO | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $61.24 |
52-Week Low | $2.78 | $51.20 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
VWO trades at $60.49, up 0.27% with a bullish technical signal from moving averages. The ETF shows strong institutional accumulation with multiple advisors increasing positions recently. Emerging markets are experiencing record capital inflows as investors diversify beyond US stocks, with VWO offering low-cost exposure to developing economies at a 0.06% expense ratio.
The outlook remains positive given institutional support and emerging market momentum, though risks include China's weighting impact and potential volatility. VWO's low expense ratio and 2.4% dividend yield provide competitive advantages over peers like EEM (0.69% fee) for emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
